Featured Research

from universities, journals, and other organizations

Researchers find comparable long-term outcomes between diastolic, systolic heart failure patients

Date:
January 9, 2014
Source:
Boston University Medical Center
Summary:
A new study has found comparable long-term outcomes between congestive heart failure patients with preserved ejection fraction commonly known as "diastolic heart failure" and congestive heart failure with reduced ejection fraction also known as "systolic heart failure."

A new study by researchers at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) found comparable long-term outcomes between congestive heart failure patients with preserved ejection fraction commonly known as "diastolic heart failure" and congestive heart failure with reduced ejection fraction also known as "systolic heart failure." The findings are published online in The American Journal of Cardiology.

Patients with normal percentage of blood leaving the heart each time it contracts and symptoms of heart failure are considered to have diastolic heart failure. Diastolic heart failure patients have not been as well studied as patients with systolic heart failure. Systolic heart failure patients have impaired blood ejection with each contraction of the heart, and do not derive long term benefit from the same medications.

According to the researchers, heart failure affects six million people in the U.S. alone and half of those admissions are patients with diastolic heart failure. However, there are not yet any treatments for this condition. In addition, the number of people who will develop diastolic heart failure is expected to rise as the population ages and the incidence of obesity and hypertension increases.

"An incredible amount of expensive and time-consuming resources are being spent on reducing readmissions at a national level, but have not translated into a reduction in heart failure mortality," said senior author Flora Sam, MD, associate professor of cardiovascular medicine at the Whitaker Cardiovascular Institute at BUSM and attending physician of cardiovascular medicine and heart failure at BMC.

The researchers gathered patient data from all heart failure admissions over a two-year period at BMC. Using the American Heart Association's Get-With-the-Guidelines quality improvement program, patients were reviewed for co-morbid conditions including kidney function, blood counts, and blood tests such as brain natriuretic peptide (BNP), a marker of heart failure.

The findings showed that in comparison to those with systolic heart failure, diastolic heart failure patients were older, more likely to be overweight, female and have hypertension. The one-year outcome of in-hospital morbidity and mortality was similar between diastolic and systolic heart failure patients. Though the early readmission rate in the 30 days after discharge was initially lower in patients with diastolic heart failure, this soon increased such that it was similar to those with systolic heart failure.

"This study shows the importance of refocusing our attention and resources on medication trials, which have historically reduced adverse long-term outcomes in chronic heart failure patients. Exploring medicinal treatment options for diastolic heart failure patients could potentially reduce readmissions, morbidity, mortality and long-term healthcare costs," said Sam.


Story Source:

The above story is based on materials provided by Boston University Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Rene Quiroz, Gheorghe Doros, Peter Shaw, Chang-seng Liang, Diane F. Gauthier, Flora Sam. Comparison of Characteristics and Outcomes of Patients with Heart Failure Preserved versus Reduced Left Ventricular Ejection Fraction in an Urban Cohort. The American Journal of Cardiology, 2013; DOI: 10.1016/j.amjcard.2013.11.014

Cite This Page:

Boston University Medical Center. "Researchers find comparable long-term outcomes between diastolic, systolic heart failure patients." ScienceDaily. ScienceDaily, 9 January 2014. <www.sciencedaily.com/releases/2014/01/140109132430.htm>.
Boston University Medical Center. (2014, January 9). Researchers find comparable long-term outcomes between diastolic, systolic heart failure patients. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/01/140109132430.htm
Boston University Medical Center. "Researchers find comparable long-term outcomes between diastolic, systolic heart failure patients." ScienceDaily. www.sciencedaily.com/releases/2014/01/140109132430.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins